Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients. (TriComB)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04564898|
Recruitment Status : Recruiting
First Posted : September 25, 2020
Last Update Posted : March 9, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Colorectal Cancer Metastatic||Drug: Capecitabine Drug: Bevacizumab Drug: Trifluridine/Tipiracil||Phase 1 Phase 2|
This is an open-label, multicenter, phase 1/2 study evaluating the safety and activity of trifluridine/tipiracil in combination with capecitabine and bevacizumab in mCRC. The first part (Part 1) of the study will consist in a dose-escalation assessment of the safety of the treatment in subjects with previously untreated mCRC deemed not fit for irinotecan- and/or oxaliplatin- based regimens (i. e. FOLFOX/XELOX/FOLFIRI/FOLFOXIRI with or without targeted agents).
The second part (Part 2) will be an open-label phase 2 study with a Fleming's single-stage design to evaluate the ORR of the study treatment at the recommended dose established in the first part of the study in the same patients' population.
Trifluridine/tipiracil, capecitabine and bevacizumab will be administered in 28-days cycles until progressive disease, unacceptable toxicities, or patients' refusal.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||48 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I/II Study Exploring the Safety and Activity of Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients|
|Actual Study Start Date :||January 25, 2022|
|Estimated Primary Completion Date :||September 2023|
|Estimated Study Completion Date :||March 2024|
|Experimental: trifluridine/tipiracil plus capecitabine and bevacizumab||
Part 1 • Capecitabine, 1000 mg/sqm orally twice daily on days 1-14 each 28 days
• Capecitabine, 1000 mg/sqm orally twice daily on days 1-14 each 28 days
Part 1 • Bevacizumab, 5 mg/kg IV dose over 30 minutes on days 1 and 15 each 28 days
• Bevacizumab, 5 mg/kg IV dose over 30 minutes on days 1 and 15 each 28 days
Part 1 • Trifluridine/tipiracil, dose escalation from 25 mg/sqm to 35 mg/sqm orally twice daily on days 15-19 (and days 22-26) each 28 days
• Trifluridine/tipiracil, at the recommanded dose established during part 1 orally twice daily on days 15-19 (and days 22-26) each 28 days
- recommended dose [ Time Frame: 2 years ]recommended dose of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab
- activity [ Time Frame: 3 years ]activity of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab in terms of overaal response rate per RECIST v1.1.
- quality of life for cancer patients [ Time Frame: 3 years ]quality of life as measured by EORTC QLQ-C30 questionnaire.
- quality of life for colorectal cancer patients [ Time Frame: 3 years ]quality of life as measured by EORTC QLQ-CR29 questionnaire.
- quality of life for dimensions health [ Time Frame: 3 years ]quality of life as measured by EuroQol EQ-5D questionnaire.
- survival [ Time Frame: 3 years ]efficacy of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab in terms of progression-free survival and overall survival
- bioavailability [ Time Frame: 2 years ]Absolute and relative bioavailability of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab.
- Steady state concentration [ Time Frame: 2 years ]Steady state concentration of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab.
- Therapeutic index [ Time Frame: 2 years ]Therapeutic index of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab.
- Volume of distribution [ Time Frame: 2 years ]Volume of distribution of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab.
- Half-life [ Time Frame: 2 years ]Plasma half-life of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab.
- Clearance [ Time Frame: 2 years ]Clearance of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Written informed consent to study procedures.
- Histologically proven diagnosis of colorectal cancer.
- Metastatic colorectal cancer not previously treated with chemotherapy for metastatic disease.
- At least one measurable lesion according to RECIST1.1.
- Age ≥ 18 years.
- ECOG PS ≤ 1.
- Life expectancy of at least 12 weeks.
- Previous adjuvant fluoropyrimidine-based chemotherapy allowed only if more than 12 months elapsed between the end of adjuvant and first relapse.
- Availability of archival tumour tissue (primary tumour and metastases or at least one of the two) for biomarker analysis.
- Availability of blood sample for biomarker analysis.
- Previously not eligible for a chemotherapy doublet or triplet (oxaliplatin and/or irinotecan-based combination).
- Neutrophils ≥1.5 x 109/L, Platelets ≥100 x 109/L, Hemoglobin ≥ 9 g/dl.
- Total bilirubin ≤1.5 fold the upper-normal limits (UNL), AST (SGOT) and/or ALT (SGPT) ≤ 2.5 x UNL (or <5 x UNL in the case of liver metastases), alkaline phosphatase ≤ 2.5 x UNL (or <5 x UNL in case of liver metastases).
- Creatinine clearance ≥ 50 mL/min or serum creatinine ≤1.5 x UNL.
- Male subjects with female partners of childbearing potential must be willing to use adequate contraception as approved by the investigator (barrier contraceptive measure or oral contraception).
- Women of childbearing potential must have a negative blood pregnancy test at the baseline visit. For this trial, women of childbearing potential are defined as all women after puberty, unless they are postmenopausal for at least 12 months, are surgically sterile, or are sexually inactive.
- Subjects and their partners must be willing to avoid pregnancy during the trial and until 6 months after the last trial treatment.
- Will and ability to comply with the protocol.
- Radiotherapy to any site within 4 weeks before the study.
- Previous treatment with trifluridine/tipiracil, bevacizumab and capecitabine (previous treatment with capecitabine was permitted only in the adjuvant setting and if more than 12 months elapsed between the end of adjuvant and first relapse).
- Untreated brain metastases or spinal cord compression or primary brain tumors.
- History or evidence upon physical examination of CNS disease unless adequately treated.
- Clinical signs of malnutrition.
- Active uncontrolled infections or other clinically relevant concomitant illness contraindicating chemotherapy administration.
- Evidence of bleeding diathesis or coagulopathy.
- Uncontrolled hypertension and prior history of hypertensive crisis or hypertensive encephalopathy.
- Clinically significant (i.e. active) cardiovascular disease for example cerebrovascular accidents (≤6 months), myocardial infarction (≤6 months), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication.
- Significant vascular disease (e.g. aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months of study enrolment.
- Any previous venous thromboembolism ≥ NCI CTCAE Grade 4.
- History of abdominal fistula, GI perforation, intra-abdominal abscess or active GI bleeding within 6 months prior to the first study treatment.
- Treatment with any investigational drug within 30 days prior to enrolment or 2 investigational agent half-lives (whichever is longer).
- Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of localized basal and squamous cell carcinoma or cervical cancer in situ.
- Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, or inability to take oral medication.
- Known hypersensitivity to trial drugs or hypersensitivity to any other component of the trial drugs.
- Any concomitant drugs contraindicated for use with the trial drugs according to the product information of the pharmaceutical companies.
- Pregnant or lactating women. Women of childbearing potential with either a positive or no pregnancy test at baseline. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential. Sexually active males and females (of childbearing potential) unwilling to practice contraception (barrier contraceptive measure or oral contraception) during the study and until 6 months after the last trial treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04564898
|Contact: Chiara Cremolini, MD, PhDfirstname.lastname@example.org|
|Contact: Laura Delliponti, MDemail@example.com|
|Fondazione IRCCS Istituto Nazionale Tumori||Not yet recruiting|
|Milano, MI, Italy, 20133|
|Contact: Filippo Pietrantonio, MD Filippo.Pietrantonio@istitutotumori.mi.it|
|Principal Investigator: Filippo Pietrantonio|
|Azienda Ospedaliero Universitaria Pisana||Recruiting|
|Pisa, PI, Italy, 56126|
|Contact: Gianluca Masi, MD +39050992466 firstname.lastname@example.org|
|Contact: Chiara Cremolini, MD +39050992192 email@example.com|
|Principal Investigator: Gianluca Masi, MD|
|Sub-Investigator: Chiara Cremolini, MD|
|Study Chair:||Chiara Cremolini, MD, PhD||Fondazione GONO|
|Responsible Party:||Gruppo Oncologico del Nord-Ovest|
|Other Study ID Numbers:||
|First Posted:||September 25, 2020 Key Record Dates|
|Last Update Posted:||March 9, 2023|
|Last Verified:||March 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||No|
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Antineoplastic Agents, Immunological
Angiogenesis Modulating Agents
Physiological Effects of Drugs
Molecular Mechanisms of Pharmacological Action